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Renin-Angiotensin System
Inhibition for Aortic Stenosis*
“A II, Bruté?”
Gerard P. Aurigemma, MD,
John F. Keaney, JR, MD
orcester, Massachusetts
In the developed world, aortic stenosis (AS) is the most
prevalent valvular heart disease and, after hypertension
and coronary artery disease, the most common heart
disease overall in Europe and North America (1). In the
elderly, the prevalence of AS has been reported to be
between 2% and 9% (2,3). Aortic sclerosis, the precursor
of AS, has been found in 29% of subjects older than 65
years (4). Since AS is a degenerative disease, the avail-
ability of echocardiography and the increasing mean age
of the population will ensure a steady stream of these
patients.
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Although there is no question that symptomatic AS
mandates surgery, management of many other AS patients
is not as clearcut, either because symptoms are vague or the
patient is considered too old or frail to survive aortic valve
replacement. It is also important to realize that many
patients with AS will experience cardiovascular events not
strictly due to AS itself (5,6). Although its rate of progres-
sion is variable, calcific AS generally worsens over time. At
present, there is no proven therapy to retard the progression
of milder forms of the disease, which are usually the ones
found by echocardiography. Because we can now follow AS
progression by echocardiography/Doppler, much recent
work has focused on better refining the natural history of the
disease (1,7) and developing medical treatment to delay or
even arrest its progression (1,8). In fact, since AS is often
found in an asymptomatic phase, or even incidentally, there
is a unique opportunity for secondary or even primary
prevention of non-AS events. This is the context for the
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These investigators performed a retrospective study of the
population of Tayside, Scotland, which included data con-
cerning echocardiography, comprising more than 110,000
scans performed on patients with a diagnosis of AS from
1993 to 2008. Cox regression model (adjusted for con-
founding variables) and propensity score analysis were
used to assess the impact of treatment with angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin
receptor blockers (ARBs)—renin-angiotensin system
(RAS) inhibition— on all-cause mortality and on cardio-
vascular events. Of the total of 2,117 patients with AS
(mean age 73  12 years), approximately one-third were
being treated with either ACEIs or ARBs. Over a mean
follow-up of 4.2 years, patients so treated experienced
one-fourth fewer cardiovascular events than those not so
treated, and this group had a similarly lower rate of
all-cause mortality (9).
This study suggests an important benefit of RAS inhibi-
tion in patients with AS, which might seem like heresy.
However, we should better understand the patients being
studied, the nature of the study, and the possible biological
mechanisms to decide whether treatment options for
asymptomatic patients with moderate or more severe AS
should now include RAS inhibition. Based on the registry
nature of the study, there are important things that we
cannot know. Symptom status cannot be ascertained, al-
though because symptomatic AS is a class I indication for
aortic valve replacement (10), it is likely that most patients
were asymptomatic. Second, we are not certain exactly why
patients were treated with RAS inhibition. The population
comprised people in their 70s with, on average, moderate to
severe AS by a mean Doppler gradient. The prevalence of
diabetes and left ventricular dysfunction was significantly
higher in the RAS group, as was the prevalence of treatment
with beta-blockers and statins, which was more than 3 times
higher than in the non-RAS group, suggesting a higher
burden of atherosclerotic disease. Because the 2 groups
varied significantly, the authors used propensity score
matching as a means of accounting for nonrandom assign-
ment to the 2 groups (11). However, in this subset, the
observed effect of ACEI/ARB assignment persisted, sug-
gesting a true effect of the treatment rather than confound-
ing. Although comforting, the use of propensity score
matching does not rule out confounding, particularly from
variables that were not measured in the cohort. In particular,
there is a significant chance that patients denied RAS
inhibition might have been deemed to be at too high a risk
because of renal insufficiency or other comorbid conditions
to tolerate the drugs (12).
Are the findings plausible biologically? To answer this
question, we should recall the important change in
thinking about the pathogenesis of AS that has occurred
over the past 2 decades, namely, the recognition that
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ble, as the authors speculate, that the atherosclerotic
plaque–stabilizing effects and consequent reduction in
cardiovascular events conferred by ACEIs could possibly
explain the early divergence of survival curves observed in
the current study. This contention is supported by
abundant data that activation of the renin-angiotensin-
aldosterone axis is known to impair vascular homeostasis.
Indeed, endothelial dysfunction, inflammation, and
thrombosis are all known consequences of RAS activa-
tion (14).
Do the results make sense clinically? The answer, in our
opinion, is “‘yes.” First, it is clear that this was a high-risk
population (Fig. 1), perhaps more easily permitting the
detection of a signal of benefit of RAS inhibition. As the
Figure 1 shows, the mortality in the study group was similar
to that found in the Pellikka et al. (7) long-term follow-up
study of asymptomatic patients with severe AS. The event
rate was slightly worse than that in the placebo group of
HOPE and patients slightly younger in mean age but with
proven atherosclerotic disease (or diabetes plus 1 or more
risk factors) (13). Interestingly, the outcome of the present
study is reminiscent of HOPE, in which RAS inhibition
with ramipril was associated with a relative risk reduction of
26% for cardiovascular death (24% in the current study) and
an all-cause mortality relative risk reduction of 16% (13)
(23% in the current study). Thus, the results of Nadir et al.,
in our opinion, are plausible in view the beneficial effect of
RAS inhibition in patients with atherosclerotic disease.
It is also important to not overlook the potential antihy-
pertensive effects of RAS inhibition in explaining the
findings reported by Nadir at al. (9). Blood pressure data
were available for only 16% of the entire population and the
details of blood pressure acquisition were not controlled.
Given that many agents inhibiting the RAS axis are
available in once-daily preparations, it is possible that real
changes in blood pressure (either ambulatory or nocturnal)
could have been missed in this study. Thus, it is possible
that the ACEI/ARB population could have had a small, but
significant effect on blood pressure that contributed to the
findings (15).
Other speculative mechanisms for which no data are
provided include reduction in fibrosis in response to pres-
sure overload (16) and the possibility that RAS inhibition
may also attenuate the progression of hypertrophy in this
pressure load situation, as has been shown in hypertension
(17) and in the HOPE study (18). Hypertrophy regression
or even lack of progression is of proven benefit (18). Finally,
the study does not permit the delineation of whether RAS
inhibition was associated with less progression of the he-
modynamic valvular lesion, although other studies on this
topic indicate that this was unlikely (1).
There has been a long-standing concern that vasodilation
in the face of fixed left ventricular outflow obstruction is
contraindicated and life threatening, and discussion of the
role of vasodilator therapy does not find its way into thevalve disease guidelines for AS (10). Perhaps the importance
of the current data is that they make us rethink this notion.
O’Brien et al. (19) demonstrated that ACEIs are safe and
well tolerated in patients with mild to moderate AS with
preserved left ventricular function. Chockalingam et al. (20)
studied the use of ACEIs in symptomatic patients with
severe AS who were not candidates for surgery. Given the
atherosclerotic ”substrate” of calcific AS, many patients will
already be treated with these agents, as the physicians in
Tayside, Scotland, show us.
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